PORTALAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Portalac, and when can generic versions of Portalac launch?
Portalac is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in PORTALAC is lactulose. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Portalac
A generic version of PORTALAC was approved as lactulose by HIKMA on July 3rd, 1995.
Summary for PORTALAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 29 |
Clinical Trials: | 1 |
Patent Applications: | 3,632 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PORTALAC at DailyMed |
Recent Clinical Trials for PORTALAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tampa General Hospital | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for PORTALAC
US Patents and Regulatory Information for PORTALAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solvay | PORTALAC | lactulose | SOLUTION;ORAL, RECTAL | 072374-001 | Mar 22, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |